Welcome to our dedicated page for Cocrystal Pharma SEC filings (Ticker: COCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides organized access to Cocrystal Pharma, Inc. (Nasdaq: COCP) SEC filings, allowing readers to review the company’s official regulatory disclosures alongside AI-generated highlights. Cocrystal is a clinical-stage biotechnology company developing structure-based antiviral therapeutics targeting influenza viruses, coronaviruses, noroviruses and hepatitis C viruses, and its filings describe how these programs are financed and advanced.
Here you can review current reports on Form 8-K, which Cocrystal uses to disclose material events. Recent 8-K filings have reported quarterly financial results, FDA Investigational New Drug (IND) clearance and a Study May Proceed Letter for a Phase 1b human challenge study with CDI-988, an oral broad-spectrum 3CL protease inhibitor for norovirus, as well as an NIH Small Business Innovation Research (SBIR) Phase I award supporting an influenza A/B polymerase complex program. Other 8-Ks detail registered direct offerings and private placements of common stock and warrants, including insider participation and the terms of securities purchase agreements.
The page also links to registration statements such as the Form S-1 filed in 2025, which registers the resale of shares issuable upon exercise of outstanding warrants originally issued in a private placement concurrent with a registered direct offering. These documents outline the company’s capital structure, risk factors and use of proceeds related to COCP shares and associated warrants.
Stock Titan’s tools surface AI-powered summaries of lengthy filings, helping users quickly understand key points from 8-Ks, S-1 registration statements and other reports without reading every page. Investors can also track disclosures related to equity financings, warrant terms and listing information for COCP on The Nasdaq Capital Market. This filings hub is intended as a starting point for deeper review of Cocrystal’s official SEC documents on EDGAR.
Cocrystal Pharma, Inc. filed a current report to share that it has released its financial results for the fiscal quarter ended June 30, 2025. On August 14, 2025, the company issued a press release detailing its results of operations and financial condition, which is furnished as Exhibit 99.1 to this report. The company notes that this information is furnished, not filed, so it is not subject to certain liability provisions and is not automatically incorporated into other securities filings.